Abstract
-
Objectives
- Laparoscopy-assisted distal gastrectomy (LADG) is a common surgical procedure that has recently been accepted as safe and feasible for the treatment of early gastric cancer. There have been many efforts to expand the indications of LADG to include the treatment of advanced gastric cancer. The aim of this study was to determine the usefulness of noncompliance rate as an indicator for D2 lymph node dissection (LND) validation in LADG.
-
Methods
- The subjects were 48 patients who underwent distal gastrectomy with D2 LND at Kosin University Gospel Hospital from October to December 2010. Of them, 28 underwent LADG and 20 underwent open distal gastrectomy (ODG). We compared several factors including noncompliance rate to validate D2 LND.
-
Results
- There were no significant differences in clinicopathologic factors except for BMI and tumor depth between the two groups. The average number of retrieved lymph nodes was significantly greater in the ODG group (45.9 ± 2.9) than in the LADG group (35.5 ± 2.0). The noncompliance rate was 43% in the LADG group and 40% in the ODG group with no significant difference.
-
Conclusions
- In terms of no difference of noncompliance rate, LADG with D2 lymph node dissection is a safe, feasible and oncologicallycamparable with open gastrectomy. A large scaled prospective randomized trial should be needed to confirm the benefit of LADG.
-
Keywords: Advanced gastric cancer; Gastric neoplasms; Laparoscopy-assisted distal gastrectomy; Noncompliance rate
Table 1.Patient clinicopathologic characteristics
Variables |
LADG (n = 28) |
ODG (n = 20) |
P
|
Sex |
M |
21 |
15 |
1.000 |
|
F |
7 |
5 |
|
BMI |
|
23.7 ± 0.49 |
22.0 ± 0.45 |
0.019 |
T stage |
T1 |
26 |
8 |
0.001 |
|
T2 |
1 |
2 |
|
|
T3 |
1 |
5 |
|
|
T4 |
0 |
5 |
|
N stage |
N0 |
27 |
12 |
0.015 |
|
N1 |
1 |
4 |
|
|
N2 |
0 |
2 |
|
|
N3 |
0 |
2 |
|
Anastomosis |
Billroth I |
23 |
16 |
0.856 |
|
Billroth II |
5 |
4 |
|
Table 2.Patient surgical outcomes
Variables |
LADG (n = 28) |
ODG (n = 20) |
P
|
Estimated blood loss |
117.8 ± 18.2 |
230.0 ± 27.2 |
0.002 |
Op. time (min.) |
199.6 ± 11.4 |
190.7 ± 7.7 |
0.521 |
Retrieved LN |
35.5 ± 2.0 |
45.9 ± 2.9 |
0.006 |
Noncompliance rate |
0.43 |
0.4 |
0.847 |
Hospital stay (days) |
7.2 |
8.4 |
0.678 |
First flatus (days) |
2.7 |
3.3 |
0.785 |
Starting semi-liquid diet |
3 |
3 |
1 |
References
- 1.Kitano S, Shiraishi N, Kakisako K, Yasuda K, Inomata M, Adachi Y. Laparoscopy-assisted Billroth-I gastrectomy (LADG) for cancer: our 10 years' experience. Surg Laparosc Endosc Percutan Tech 2002;12:204–7.ArticlePubMed
- 2.Hur H, Jeon HM, Kim W. Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy for T2b advanced gastric cancers: three years' experience. J Surg Oncol 2008;98:515–9.ArticlePubMed
- 3.Lee J, Kim W. Long-term outcomes after laparoscopy-assisted gastrectomy for advanced gastric cancer: analysis of consecutive 106 experiences. J Surg Oncol 2009;100:693–8.ArticlePubMed
- 4.Hwang SI, Kim HO, Yoo CH, Shin JH, Son BH. Laparo-scopic-assisted distal gastrectomy versus open distal gastrectomy for advanced gastric cancer. Surg Endosc 2009;23:1252–8.ArticlePubMed
- 5.Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998;1:10–24.ArticlePubMedPDF
- 6.Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069–77.ArticlePubMed
- 7.Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522–30.ArticlePubMedPMC
- 8.Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002;5:1–5.Article
- 9.Huang JL, Wei HB, Zheng ZH, Wei B, Chen TF, Huang Y, et al. Laparoscopy-assisted D2 radical distal gastrectomy for advanced gastric cancer. Dig Surg 2010;27:291–6.ArticlePubMed
- 10.Tokunaga M, Hiki N, Fukunaga T, Nohara K, Katayama H, Akashi Y, et al. Laparoscopy-assisted distal gastrectomy with D2 lymph node dissection following standardization--a preliminary study. J Gastrointest Surg 2009;13:1058–63.ArticlePubMed
- 11.Lee JH, Kim YW, Ryu KW, Lee JR, Kim CG, Choi IJ, et al. A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. Ann Surg Oncol 2007;14:3148–53.ArticlePubMed
- 12.Katai H, Sasako M, Fukuda H, Nakamura K, Hiki N, Saka M, et al. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer 2010;13:238–44.ArticlePubMed
- 13.COACT. Feasibility Study of Laparoscopy-assisted D2 Distal Gastrectomy to Treat Advanced Gastric Cancer (COACT_1001). 2010;[updated 2010-06-16]; Available from:.http://www.clinicaltrial.gov/ct2/show/NCT01088204?term=COACT&rank=3.
- 14.KLASS. Standardization of D2 Lymphadenectomy and Surgical Quality Control: KLASS-02-QC. 2011;[updated January 25, 2011]; Available from:.http://www.clinicaltrial.gov/ct2/show/NCT01283893?term=KLASS&rank=2.
Citations
Citations to this article as recorded by